Chemo-radiotherapy in non-small cell lung cancer: the role of gemcitabine

Ann Oncol. 2006 May:17 Suppl 5:v52-4. doi: 10.1093/annonc/mdj950.

Abstract

Gemcitabine (2'-2'-difluorodeoxycytidine) is a well-known cytotoxic drug and a potent radio-enhancer. We herein report the in vitro evidence of its activity, and the clinical experiences when this drug is administered concurrently with radiation. The phase I-II trials are analyzed, focusing on the recent ability to deliver irradiation with low incidence of side effects.

Publication types

  • Comparative Study
  • Evaluation Study
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / radiotherapy*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Gemcitabine
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / radiotherapy*
  • Neoadjuvant Therapy
  • Radiation-Sensitizing Agents / therapeutic use*

Substances

  • Radiation-Sensitizing Agents
  • Deoxycytidine
  • Gemcitabine